Drugs /

dotap:cholesterol-fus1 liposome complex

Back to Drugs List

Overview

NCI Definition [1]:
A formulation composed of DOTAP:cholesterol liposomal nanoparticles complexed with a plasmid expression cassette encoding human FUS1 protein, with potential antineoplastic activity. Upon administration, DOTAP:chol-Fus1 liposome complex accumulates mainly in the lungs and particularly in cancer cells. Upon transfer of the Fus1 gene into tumor cells, the expression of Fus1 may induce tumor cell apoptosis and suppress tumor cell proliferation. Fus1, a potent tumor-suppressor protein, is present in normal, healthy cells but often absent in certain cancer cells. DOTAP:cholesterol liposome is composed of cationic lipid dioleoyl-trimethylammonium propane (DOTAP) and cholesterol at a molar ratio of 1:1.

Clinical Trials

View Clinical Trials for dotap:cholesterol-fus1 liposome complex

Dotap:cholesterol-fus1 liposome complex has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating dotap:cholesterol-fus1 liposome complex, 1 is phase 1/phase 2 (1 open).

EGFR A763_Y764insFQEA, EGFR Exon 19 Deletion, and EGFR Exon 19 Insertion are the most frequent biomarker inclusion criteria for dotap:cholesterol-fus1 liposome complex clinical trials.

Non-small cell lung carcinoma is the most common disease being investigated in dotap:cholesterol-fus1 liposome complex clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Dotap:cholesterol-Fus1 Liposome Complex
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating dotap:cholesterol-fus1 liposome complex and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
dotap:cholesterol-fus1, dotap:chol-fus1, ingn 401, dotap:chol-fus1 liposome complex
NCIT ID [1]:
C91708

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.